By Allison Proffitt
September 11, 2017 | Kevin Hrusovsky, CEO at Quanterix, sees a handheld future for diagnostics. Breast cancer diagnostics at home, concussion diagnostics on the sidelines, Hrusovsky sees a future that is portable and delivers results in real time.
I caught up with Hrusovsky on the exhibit hall floor at the Next Generation Dx Summit last month between his track presentation and his seat on the plenary panel.
He showed off the Quanterix SR-Plex Ultra-Sensitive Biomarker Detection System, a benchtop diagnostic platform using single molecule measurements to assess previously undetectable proteins. The sensitivity of the SR-Plex is astonishing, Hrusovsky said: “In this technology here it’s equivalent to being able to see a grain of sand in 2,000 Olympic-sized swimming pools.” But he expects that sensitivity to improve, and with it the range of diagnostic applications.
Quanterix’s Simoa technology can identify proteins in blood that indicate brain injury and the company is working on identifying Alzheimer’s Disease and dementia much earlier from blood markers as well. There are also oncology and cardiology applications, he said.
">
Highlights:
00:35 chronic traumatic encephalopathy
1:04 Quanterix’s SR-Plex
2:38 the best kept secret about the new platform
3:20 diagnosing concussion in youth football today and second impact syndrome
4:37 CLIA Waiver for point of care diagnostics testing
5:25 future of diagnostics: making health screens at-home procedures